Theracryf Plc logo

Theracryf Plc(LSE) TCF

Market Cap£4.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-99%
5 Year-97%
1 Year-16%
1 Month-5%
£0.00
-10.53%
-0.00Today
Theracryf Plc last closing stock price
MetricPriceDate
Last closeGBX 0.182026-10-01
Theracryf Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.88%GBX 0.172026-09-24
1 month-5.26%GBX 0.192026-09-01
3 month-16.28%GBX 0.222026-07-03
Year to date-10%GBX 0.202025-12-31
1 year-16.28%GBX 0.222025-10-01
3 year-91.43%GBX 2.102023-10-02
5 year-96.92%GBX 5.852021-10-01
Since inception-99.48%GBX 0.352015-10-21

Theracryf Plc Financials at a Glance

Market Cap

£4.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£5.47M

EPS (TTM)

-£0.00

P/E Ratio

-1.12

Dividend

£0.00

Beta (Volatility)

-0.08 (Low)

Price

£0.00

Volume

2,671,600

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.00

Estimated Earnings Date

Dec 17, 2026

TCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theracryf Plc

Evgen Pharma plc is a UK-based pharmaceutical company focused on developing innovative sulforaphane-based medications to combat various cancers and inflammatory conditions. Founded in 2014, the company utilizes its proprietary Sulforadex technology to stabilize sulforaphane, with its lead drug candidate, SFX-01, currently in clinical trials.

Products and Services
  • SFX-01: Lead drug candidate for metastatic breast cancer and glioblastoma
  • Preclinical investigations for haematological malignancies
  • Out-licensing services for proprietary technology
Growth Outlook
  • Ongoing Phase II trials for SFX-01 indicate potential market entry
  • Strong focus on expanding research into additional cancer types
  • Partnership opportunities for technology out-licensing may enhance revenue
Financial Highlights
  • Recent quarterly revenue of 396,000 GBP shows growth from previous periods
  • Cash reserves of 2,004,000 GBP as of March 2024 provide operational stability
  • Current ratio of 2.29 indicates strong liquidity position
Evgen Pharma plc operates in the biotechnology sector, emphasizing the development of treatments that leverage the health benefits of sulforaphane. The company’s lead candidate, SFX-01, is undergoing critical clinical trials, which could pave the way for significant advancements in cancer treatment. The focus on expanding research into additional cancer types and the potential for out-licensing its technology may provide avenues for future revenue growth. Recent financial data reflects a positive trajectory, with increasing cash reserves and a solid liquidity position, positioning the company favorably for upcoming challenges and opportunities in the pharmaceutical landscape.
AI Generated • Sep 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

9

CEO

Huw Jones, PhD

Website

www.evgen.com

Headquarters

Nether Alderley, CH SK10 4TG, GB

TCF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-93.92%

Return on Capital

-135.08%

Return on Assets

-73.35%

Earnings Yield

-89.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£4.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.73B

Volume

2.67M

Avg. Volume

2.10M

Financials (TTM)

Gross Profit

-£913.00K

Operating Income

-£5.82M

EBITDA

-£5.67M

Operating Cash Flow

-£4.92M

Capital Expenditure

-£17.00K

Free Cash Flow

-£4.94M

Cash & ST Invst.

£1.54M

Total Debt

£11.00K

Theracryf Plc Performance Analysis

Theracryf Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31GBP 442,000N/A
20242024-03-31GBP 396,000-10.4%
20252025-03-31GBP 0N/A
20262026-03-31GBP 0N/A
Theracryf Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30N/A
Q42025-03-31N/A
Q22025-09-30N/A
Q42026-03-31N/A
Theracryf Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31GBP -0.0148.5%
20242024-03-31GBP -0.01-22.4%
20252025-03-31GBP -0.00-68.4%
20262026-03-31GBP -0.00-55.6%
Theracryf Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-3026.2%
Q42025-03-3175.6%
Q22025-09-30100.0%
Q42026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£12.00K

-140.0%

Gross Margin

0.00%

N/A

Market Cap

£4.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£546.46K

N/A

Employees

9

N/A

Net Income

-£2.22M

-32.2%

EBITDA

-£2.31M

-10.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£1.54M

-23.0%

Total Debt

£11.00K

N/A

Accounts Receivable

£747.00K

+50.3%

Inventory

£0.00

+100.0%

Long Term Debt

£0.00

N/A

Short Term Debt

£11.00K

N/A

Return on Assets

-73.35%

N/A

Return on Invested Capital

-1.18%

N/A

Free Cash Flow

-£1.87M

-8.2%

Operating Cash Flow

-£1.85M

-7.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRX.LTissue Regenix Group plc
£0.07+0.00%
PRM.LProteome Sciences plc
£0.01-0.34%
N4P.LN4 Pharma Plc
£0.00+0.00%
CRTX.LCRISM Therapeutics Corporation
£0.10+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About TCF

What is the current price of Theracryf Plc?

Theracryf Plc is trading at £0.00 per share.

What is the 52-week range for Theracryf Plc?

Over the past 52 weeks, Theracryf Plc has traded between £0.00 and £0.00.

How much debt does Theracryf Plc have?

As of the most recent reporting period, Theracryf Plc reported total debt of £11.00K.

How much cash does Theracryf Plc have on hand?

Theracryf Plc reported £471.00K in cash and cash equivalents in its most recent financial results.

What is Theracryf Plc’s dividend yield?

Theracryf Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services